Assessment and treatment of hot flushes and menopausal mood disturbance

Psychiatric Clinics of North America

Volumn 26, Issue 3, 2003, Pages 563-580

  Joffe, Hadine ^a   Soares, Claudio N ^a   Cohen, Lee S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CLONIDINE; ESTRADIOL; FLUOXETINE; FOLLITROPIN; GABAPENTIN; ISOFLAVONE; MEGESTROL ACETATE; PAROXETINE; VENLAFAXINE;

BEHAVIOR THERAPY; BREAST CANCER; CANCER RISK; CLINICAL FEATURE; COGNITION; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DRUG SAFETY; ESTROGEN THERAPY; GALLBLADDER DISEASE; HORMONAL REGULATION; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP; THERMOREGULATION;

EID: 0141843502     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(03)00045-5     Document Type: Review

References (114)

1. United States Bureau of the Census. Projections of the total resident population by 5-year age groups, and sex with special age categories: middle series, 1999-2000. Available at: http://www.census.gov/population/projections/nation/summary/np-t3-a.txt. Accessed December 2001.
2. Menopause Core Curriculum Study Guide. Cleveland (OH): North American Menopause Society; 2000.
3. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression: results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:213-20.
4. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
5. Jaszmann L, van Lith ND, Zaat JCA. The perimenopausal symptoms: the statistical analysis of a survey. Med Gynaecol Sociol 1969;4:268-77.
6. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86.
7. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
8. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741-4.
9. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-8.
10. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol 2001;2:199-204.
11. Anderson E, Hamburger S, Liu JH, Rebar RW. Characteristics of menopausal women seeking assistance. Am J Obstet Gynecol 1987;156:428-33.
12. Grady D. Postmenopausal hormones-therapy for symptoms only. N Engl J Med 2003;348:1835-7.
13. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;17:17.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
15. Gass MLS, Utian WH. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy, Press Release, October 2002.
16. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
17. Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition-an analysis of FSH, oestradiol and inhibin. Eur J Endocrinol 1994;130:38-42.
18. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-8.
19. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88:1516-22.
20. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-30.
21. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80:3537-45.
22. Stearns V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet 2002;360:1851-61.
23. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8.
24. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26:573-9.
25. Woodward S, Arfken CL, Ditri DW, Freedman RR. Ambient temperature effects on sleep and mood in menopausal women. Sleep 1999;22:S224-5.
26. Woodward S, Freedman RR. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep 1994;17:497-501.
27. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70.
28. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-7.
29. Rebar RW, Spitzer IB. The physiology and measurement of hot flushes. Am J Obstet Gynecol 1987;156:1284-8.
30. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
31. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-6.
32. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36:155-64.
33. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
34. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.
35. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
36. Barton DL, Loprinzi C, Gostout B. Current management of menopausal symptoms in cancer patients. Oncology (Huntingt) 2002;16:67-72, 74; discussion 75-6, 79-80.
37. Sumner BE, Grant KE, Rosie R, et al. Effects of tamoxifen on serotonin transporter and 5- hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Brain Res Mol Brain Res 1999;73:119-28.
38. McDonnell DP, Wijayaratne A, Chang CY, Norris JD. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol 2002;90:35F-43F.
39. Zhou W, Koldzic-Zivanovic N, Clarke CH, et al. Selective estrogen receptor modulator effects in the rat brain. Neuroendocrinology 2002;75:24-33.
40. Cyr M, Landry M, Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000;23:69-78.
41. Haas S, Walsh B, Evans S, et al. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988;71:671-6.
42. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52.
43. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;13:883-8.
44. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.
45. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473-9.
46. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-45.
47. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-6.
48. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93.
49. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-8.
50. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
51. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-45.
52. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068-74.
53. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13.
54. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992;167:436-9.
55. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-64.
56. Owens JF, Matthews KA. Sleep disturbance in healthy middle-aged women. Maturitas 1998;30:41-50.
57. Shaver JL, Zenk SN. Sleep disturbance in menopause. J Womens Health Gend Based Med 2000;9:109-18.
58. Committee DCS. Diagnostic and coding manual. In: Thorpy MJC, editor. Rochester (MN): American Sleep Disorders Association; 1990.
59. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
60. Manber R, Armitage R. Sex, steroids, and sleep: a review. Sleep 1999;22:540-55.
61. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988;11:556-61.
62. Scharf MB, McDannold MD, Stover R, et al. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clin Ther 1997;19:304-11.
63. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979;242:2405-14.
64. Polo-Kantola P, Erkkola R, Helenius H, et al. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol 1998;178:1002-9.
65. Purdie DW, Empson JA, Crichton C, Macdonald L. Hormone replacement therapy, sleep quality and psychological wellbeing. Br J Obstet Gynaecol 1995;102:735-9.
66. Thomson J. Double blind study on the effect of oestrogen on sleep, anxiety and depression in perimenopausal women: preliminary results. Proc R Soc Med 1976;69:829-30.
67. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001;8:10-6.
68. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298-306.
69. McKinlay JB, McKinlay SM, Brambilla D. The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 1987;28:345-63.
70. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
71. Schmidt PJ, Rubinow DR. Menopause-related affective disorders: a justification for further study. Am J Psychiatry 1994;148:844-52.
72. Altshuler LL, Cohen LS, Moline ML, et al. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med 2001;1-107.
73. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20.
74. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-34.
75. Pearce J, Hawton K, Blake F, et al. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res 1997;42:177-86.
76. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31:134-40.
77. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women. A preliminary report. Am J Psychiatry 2003 (in press). 2000.
78. Morrison M. Estrogen and mood in aging women: an update. Paper presented at the 15th Annual Meeting of American Association of Geriatric Psychiatry, Orlando, FL, February 22, 2002.
79. Joffe H, Groninger H, Soares C, et al. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gend Based Med 2001;10:999-1004.
80. La Rue A. Aging and neuropsychological assessment. New York: Plenum Press; 1992.
81. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
82. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-57.
83. Duka T, Tasker R, McGowan JF. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology (Berl) 2000;149:129-39.
84. Caldwell B, Watson R. An evaluation of psychologic effects of sex hormone administration in aged women: results after six months. J Gerontol 1952;7:228-44.
85. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate ('Harmogen') and its effect on memory. Curr Med Res Opin 1976;4:303-6.
86. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand 1977;64(Suppl):1-91.
87. Joffe H, Yurgulen-Todd D, Hall JE, et al. Estrogen replacement reduces errors in verbal preservation, but does not enhance other cognitive domains in menopausal women: a randomized, double-blind, placebo-controlled study. Paper presented at the Endocrine Society 85th Annual Society Meeting, Philadelphia, June 20, 2003.
88. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95.
89. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997;48:S8-15.
90. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489-99.
91. Binder EF, Schechtman KB, Birge SJ, et al. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 2001;38:137-46.
92. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med 2002;113:543-8.
93. Polo-Kantola P, Portin R, Polo O, et al. The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol 1998;91:459-66.
94. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-202.
95. Portin R, Polo-Kantola P, Polo O, et al. Serum estrogen level, attention, memory and other cognitive functions in middle-aged women. Climacteric 1999;2:115-23.
96. Rauramo L, Lagerspetz K, Engblom P, Punnonen R. The effect of castration and peroral estrogen therapy on some psychological functions. Front Horm Res 1975;3:94-104.
97. Reboussin BA, Greendale GA, Espeland MA. Effect of hormone replacement therapy on self-reported cognitive symptoms: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. Climacteric 1998;1:172-9.
98. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci 2000;12:407-14.
99. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-5.
100. Berman KF, Schmidt PJ, Rubinow DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997;94:8836-41.
101. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000;21:373-83.
102. Resnick SM, Maki PM, Golski S, et al. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998;34:171-82.
103. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682-91.
104. Stein KD, Jacobsen PB, Hann DM, et al. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000;19:436-45.
105. Holte A. Menopause, mood and hormone replacement therapy: methodological issues. Maturitas 1998;29:5-18.
106. Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996;24:177-84.
107. Hunter M, Battersby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas 1986;8:217-28.
108. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75.
109. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy-a placebo-controlled study. Int J Fertil Menopausal Stud 1995;40:73-8.
110. Wiklund I, Berg G, Hammar M, et al. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992;14:225-36.
111. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-24.
112. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-30.
113. Skarsgard C, E Berg G, Ekblad S, et al. Effects of estrogen therapy on well-being in postmenopausal women without vasomotor complaints. Maturitas 2000;36:123-30.
114. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-7.